---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-256533"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:25:14.640852+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte subsidiary signs commercial manufacturing deal with Lonza for pneumococcal vaccine

## Summary
- Lonza will build a dedicated suite in Visp, Switzerland to manufacture drug substance for Vaxcyte's pneumococcal conjugate vaccine franchise.
- Vaxcyte GmbH pays CHF 27M repurposing fee within 30 days, credited over 10 years from commercial production start.
- Agreement term through Dec 31, 2038, renewable for three 5-year periods; termination penalty up to CHF 70M under certain conditions.
- Vaxcyte retains right to use alternate manufacturers; receives perpetual, royalty-free license to Lonza's IP for the Products.
- Pre-commercial service fees and capital expenditure contributions commence before suite certification for commercial operation.

## SEC filing metadata
- accession: 0001193125-23-256533
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/0001193125-23-256533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/d572225d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-256533
- JSON: https://secwatch.observer/filing/0001193125-23-256533.json
- Plain text: https://secwatch.observer/filing/0001193125-23-256533.txt

## Key facts
- Material Agreements
  Vaxcyte, Inc. entered into Commercial Manufacturing and Supply Agreement with Lonza Ltd (effective 2023-10-13).
  - Action: entry
  - Agreement: supply
  - Counterparty: Lonza Ltd
  - Effective: 2023-10-13
  source text: On October 13, 2023 (the “Effective Date”), Vaxcyte Switzerland GmbH (“Vaxcyte GmbH”), a Swiss limited liability company that, as of such date, was in the process of being formed by Vaxcyte, Inc. (“Vaxcyte”) (as a wholly-owned subsidiary of Vaxcyte), entered into a pre-commercial services and commercial manufacturing supply agreement (the “Commercial Manufacturing and Supply Agreement”) with Lonza Ltd (“Lonza”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/0001193125-23-256533-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.